PI3K/mTOR signaling pathways in medulloblastoma

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3141-3146

  Mohan, Avinash L ^a   Friedman, Marissa D ^a   Ormond, D Ryan ^a   Tobias, Michael ^a   Murali, Raj ^a   Jhanwar Uniyal, Meena ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Medulloblastoma; mTOR; P13K; P27; PDGF; Rapamycin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PP242; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BRAIN TUMOR; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MEDULLOBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84865675233     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gilbertson RJ: Medulloblastoma: signaling a change in treatment. Lancet Oncol 5: 209-218, 2004.
2. Sarkar C, Deb P, and Sharma MC: Medulloblastomas: New directions in risk stratification. Neurol India 54: 16-23, 2006.
3. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, Graf N, Emser A, Pietsch T, Wolff JE, Kortmann RD, and Kuehl J: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352: 978-986, 2005.
4. Edelstein K, Spiegler BJ, Fung S, Panzarella T, Mabbott DJ, Jewitt N, D'Agostino NM, Mason WP, Bouffet E, Tabori U, Laperriere N, and Hodgson DC: Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. Neuro Oncol 13: 536-545, 2011.
5. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S and Taylor MD: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29(11): 1408-1414, 2011.
6. Bhatia B, Northcott P, Hambardzumyan D, Govindarajan B, Brat DJ, Arbiser JL, Holland EC, Taylor MD and Kenney AM: Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27kip1 localization. Cancer Res 69: 7224-7234, 2009.
7. Mainwaring LM and Kenney AM: Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum. Oncogene 30: 1784-1797, 2011.
8. Bhatia B, Malik A, Fernandez-L A, and Kenney AM: p27Kip1, a double-edged sword in Shh-mediated medulloblastoma. Cell Cycle 9: 4307-4314, 2010.
9. See WL, Miller JP, Squatrito M, Holland E, Resh MD, and Koff A: Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas. Oncogene 29: 1720-1731, 2010.
10. Albert L, Karsy M, Murali R, and Jhanwar-Uniyal M: Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics 6: 255-261, 2009.
11. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, and Holland EC: PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 15: 436-448, 2008.
12. Hartmann W, Digon-Söntgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sörensen N, Wiestler OD, and Pietsch T: Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019-3027, 2006.
13. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, and Arcaro A: Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 14: 6761-6769, 2008.
14. Srivastava VK, Yasruel Z, and Nalbantoglu J: Impaired medulloblastoma cell survival following activation of the FOXO1 transcription factor. Int J Oncol 35: 1045-1051, 2009.
15. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
16. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
17. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, and Sherr CJ: The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18: 1571-1583, 1999.
18. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, and Meloche S: p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 20: 6672-6682, 2001.